Screener
Novavax NVAX Ratios & Valuation
| Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 78.6%-9.6pp | 85%-2.5pp | 93.5%+23.2pp | 91.8%+28.0pp | 88.3%+24.6pp | |
| Operating margin | -56.6%-89.2pp | -13.1%-45.9pp | 40.3%+76.8pp | 28.9%+62.9pp | 32.6%+62.3pp | |
| Net margin | -59.9%-99.1pp | -14.7%-52.9pp | 39.2%+66.7pp | 32.1%+64.3pp | 39.2%+69.0pp | |
| Efficiency | ||||||
| Asset turnover | 0.4×-0.3× | 0.5×-0.4× | 0.8×+0.4× | 0.7×+0.2× | 0.7×+0.1× | |
| Liquidity | ||||||
| Current ratio | 2.3×0.0× | 2.5×+0.4× | 2.1×+1.1× | 2.3×+1.3× | 2.4×+1.3× | |
| Per Share | ||||||
| Book value per share | -$1.16-646% | -$0.89-108% | -$0.74+82.0% | -$0.97+70.7% | $0.21+108% | |
| Valuation | ||||||
| Market capitalization | $1.27B+3.7% | $1.33B+28.6% | $1.09B-15.2% | $1.41B-30.4% | $1.05B-43.6% | |
| Price / sales | 3.1×+1.9× | 2.2×+1.4× | 1×-0.9× | 1.3×-1.0× | 1×-0.9× |
FAQ
- What are Novavax's profit margins?
- Novavax (NVAX) runs a 78.6% gross margin and a -56.6% operating margin, with a -59.9% net margin.
- Where do Novavax's ratios come from?
- Every ratio is computed from Novavax's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
